- Home
- NUVL vs ONB Comparison
NUVL vs ONB Comparison
Compare NUVL & ONB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ONB
- Stock Information
- Founded
- NUVL 2017
- ONB 1834
- Country
- NUVL United States
- ONB United States
- Employees
- NUVL N/A
- ONB N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ONB Major Banks
- Sector
- NUVL Health Care
- ONB Finance
- Exchange
- NUVL Nasdaq
- ONB Nasdaq
- Market Cap
- NUVL 6.7B
- ONB 7.4B
- IPO Year
- NUVL 2021
- ONB N/A
- Fundamental
- Price
- NUVL $75.84
- ONB $22.93
- Analyst Decision
- NUVL Strong Buy
- ONB Buy
- Analyst Count
- NUVL 11
- ONB 7
- Target Price
- NUVL $112.36
- ONB $25.00
- AVG Volume (30 Days)
- NUVL 558.9K
- ONB 3.3M
- Earning Date
- NUVL 02-25-2025
- ONB 01-21-2025
- Dividend Yield
- NUVL N/A
- ONB 2.44%
- EPS Growth
- NUVL N/A
- ONB N/A
- EPS
- NUVL N/A
- ONB 1.65
- Revenue
- NUVL N/A
- ONB $1,748,866,000.00
- Revenue This Year
- NUVL N/A
- ONB N/A
- Revenue Next Year
- NUVL N/A
- ONB $23.66
- P/E Ratio
- NUVL N/A
- ONB $13.91
- Revenue Growth
- NUVL N/A
- ONB N/A
- 52 Week Low
- NUVL $61.80
- ONB $15.36
- 52 Week High
- NUVL $113.51
- ONB $23.76
- Technical
- Relative Strength Index (RSI)
- NUVL 38.09
- ONB 62.33
- Support Level
- NUVL $69.58
- ONB $20.41
- Resistance Level
- NUVL $78.18
- ONB $21.84
- Average True Range (ATR)
- NUVL 3.03
- ONB 0.55
- MACD
- NUVL 0.04
- ONB 0.17
- Stochastic Oscillator
- NUVL 50.40
- ONB 93.68
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.